Hidradenitis suppurativa—a painful, disfiguring inflammatory skin disease marked by recurring abscesses and sinus tracts—has long lacked effective oral systemic options, leaving patients cycling through biologics, antibiotics, and surgery with inconsistent results. A pair of pivotal phase 3 trials now suggest a targeted small-molecule approach may meaningfully shift that equation.
The STOP-HS1 and STOP-HS2 trials, published in Nature Medicine, evaluated povorcitinib, a selective oral JAK1 inhibitor, in adults with moderate-to-severe hidradenitis suppurativa. Both randomized, double-blind, placebo-controlled studies demonstrated that povorcitinib significantly reduced abscess and inflammatory nodule counts—the primary endpoints used in HS research—compared with placebo. The selectivity for JAK1 is mechanistically relevant: HS pathophysiology involves dysregulated IL-17, IL-1, and other cytokine axes that signal through JAK1-STAT pathways, suggesting on-target pharmacology rather than broad immunosuppression.
These results carry weight because they replicate across two independent cohorts—a methodological bar that single-trial findings rarely meet. HS affects roughly 1% of the general population, disproportionately women and individuals with obesity, and its psychosocial burden rivals that of conditions like psoriasis and Crohn's disease. Current approved biologics, including adalimumab and secukinumab, achieve meaningful response in only a subset of patients and require injection—a meaningful barrier. An oral once-daily JAK inhibitor could substantially expand accessible treatment options.
Key caveats apply. JAK inhibitor class effects—including elevated infection risk, cardiovascular concerns, and malignancy signals flagged by regulatory agencies—mean povorcitinib will likely carry boxed warnings pending approval review. Long-term safety data beyond trial duration remain essential. Additionally, while abscess and nodule reduction is clinically meaningful, durability of response and effects on scarring and sinus tracts warrant further study. This is nonetheless a potentially practice-changing finding for a disease historically underserved by systemic therapy.